Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in ProstateCancer Purpose Chemohormonal therapy with docetaxel and androgen deprivation therapy (ADT+D) for metastatic hormone-sensitive prostatecancer improves overall survival as compared with androgen deprivation therapy (ADT) alone. We compared the quality of life (QOL) between patients with metastatic hormone-sensitive prostatecancer who were treated with ADT+D (...) and those who were treated with ADT alone. Methods Men were randomly assigned to ADT+ D (six cycles) or to ADT alone. QOL was assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P), FACT-Taxane, Functional Assessment of Chronic Illness Therapy-Fatigue, and the Brief Pain Inventory at baseline and at 3, 6, 9, and 12 months. The Wilcoxon signed rank test was used to examine changes over time. Mixed-effect models compared the QOL between arms at each time point. Results Seven hundred ninety
-4N0M0 prostatecancer (median follow-up 48.9 and 25.0 mo, respectively), and genomic data for 4960 patients from the Decipher Genomic Resource Information Database. Data were collected for 2004-2017.Multivariable Fine-Gray and Cox regressions were used to analyze prostatecancer-specific mortality (PCSM) and all-cause mortality, respectively.For Gleason 8-10 disease, using PSA 4.1-10.0ng/ml (n=38 719) as referent, the distribution of PCSM by PSA was U-shaped, with an adjusted hazard ratio (AHR (...) Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade ProstateCancer The consequences of low prostate-specific antigen (PSA) in high-grade (Gleason 8-10) prostatecancer are unknown.To evaluate the clinical implications and genomic features of low-PSA, high-grade disease.This was a retrospective study of clinical data for 494 793 patients from the National Cancer Data Base and 136 113 patients from the Surveillance, Epidemiology, and End Results program with cT1
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk ProstateCancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian ProstateCancer Group 12 Trial Adjuvant chemotherapy is standard treatment for other solid tumours, but to date has not proven effective in prostate cancer.o evaluate whether six cycles of docetaxel alone improve biochemical disease-free survival after radical prostatectomy for high-risk prostate cancer.Open-label, randomised (...) of 116 serious adverse events were recorded in Arm A and 41 in Arm B with no treatment-related deaths. Not all patients received docetaxel by protocol. The endpoint is biochemical progression and some patients received radiation treatment before the endpoint.Docetaxel without hormonal therapy did not significantly improve biochemical disease-free survival after radical prostatectomy.In this randomised trial, we tested whether chemotherapy after surgery for high-risk prostatecancer decreases the risk
Comparison of Quantitative Apparent Diffusion Coefficient Parameters with Prostate Imaging Reporting and Data System V2 Assessment for Detection of Clinically Significant Peripheral Zone ProstateCancer To compare diagnostic performance of PI-RADSv2 with ADC parameters to identify clinically significant prostatecancer (csPC) and to determine the impact of csPC definitions on diagnostic performance of ADC and PI-RADSv2.We retrospectively identified treatment-naïve pathology-proven peripheral (...) zone PC patients who underwent 3T prostate MRI, using high b-value diffusion-weighted imaging from 2011 to 2015. Using 3D slicer, areas of suspected tumor (T) and normal tissue (N) on ADC (b = 0, 1400) were outlined volumetrically. Mean ADCT, mean ADCN, ADCratio (ADCT/ADCN) were calculated. PI-RADSv2 was assigned. Three csPC definitions were used: (A) Gleason score (GS) ≥ 4 + 3; (B) GS ≥ 3 + 4; (C) MRI-based tumor volume >0.5 cc. Performances of ADC parameters and PI-RADSv2 in identifying csPC were
A Web-Based Intervention to Reduce Distress After ProstateCancer Treatment: Development and Feasibility of the Getting Down to Coping Program in Two Different Clinical Settings Distress after prostatecancer treatment is a substantial burden for up to one-third of men diagnosed. Physical and emotional symptoms and health service use can intensify, yet men are reticent to accept support. To provide accessible support that can be cost effectively integrated into care pathways, we developed (...) a unique, Web-based, self-guided, cognitive-behavior program incorporating filmed and interactive peer support.To assess feasibility of the intervention among men experiencing distress after prostatecancer treatment. Demand, acceptability, change in distress and self-efficacy, and challenges for implementation in clinical practice were measured.A pre-post, within-participant comparison, mixed-methods research design was followed. Phase I and II were conducted in primary care psychological service
Hedgehog in prostatecancer explained 29854872 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Hedgehog in prostatecancer explained. 67-68 10.18632/oncoscience.405 Buttyan Ralph R The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. Li Na N The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. Massah Shabnam S The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 Androgen Receptors Gli (...) Hedgehog Steroid Receptors prostatecancer CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 12 2018 04 21 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854872 10.18632/oncoscience.405 405 PMC5978441 Eur J Cancer. 2006 Mar;42(4):437-45 16406505 Prostate. 2014 Oct;74(14 ):1400-10 25132524 Cancer Chemother Pharmacol. 2016 Dec;78(6):1297-1304 27826729 Cell Mol Life Sci. 2000 Nov;57(12 ):1720-31 11130178 Oncogene. 2018 Apr;37(17 ):2313-2325 29429990 Horm Cancer. 2014
Germline genetic testing in prostatecancer â€“ further enrichment in variant histologies? 29854870 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Germline genetic testing in prostatecancer - further enrichment in variant histologies? 62-64 10.18632/oncoscience.403 Markowski Mark C MC Departments of Oncology and Urology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD 21287, USA. Antonarakis Emmanuel S ES Departments of Oncology and Urology, Johns Hopkins Sidney Kimmel (...) Cancer Center, Baltimore, MD 21287, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 03 29 2018 03 29 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854870 10.18632/oncoscience.403 403 PMC5978447 N Engl J Med. 2016 Aug 4;375(5):443-53 27433846 Cell. 2015 May 21;161(5):1215-1228 26000489 Eur Urol. 2017 Jul;72 (1):34-42 28259476 Cell. 2015 Nov 5;163(4):1011-25 26544944 Eur Urol. 2018 May;73
Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With ProstateCancer Androgen deprivation therapy (ADT) for prostatecancer (PCa) is associated with increased cardiovascular mortality and sudden cardiac death, with some events occurring early after initiation of ADT. Testosterone levels are inversely associated with corrected QT (QTc) interval duration; therefore, prolongation of QTc duration could be responsible for some of these events during ADT.To
Apalutamide (Erleada) - prostatecancer Drug Approval Package: ERLEADA (apalutamide) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ERLEADA (apalutamide) This review package includes Clinical Study Reports as part of a pilot project. The Clinical Study Report section provides information for pivotal clinical trials, not for all studies in the application. Company: Janssen Biotech Application Number: 210951 Orig 1 Approval Date: 02/14/2018 Persons
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostatecancer (LATITUDE): an international, randomised phase 3 trial In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostatecancer (...) , by use of the Brief Pain Inventory-Short Form (BPI-SF), Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy Prostate scale (FACT-P), and the EuroQol (EQ-5D-5L) questionnaires. PRO analyses were an exploratory endpoint. Analyses were by intention-to-treat. Results from the first pre-planned interim analysis (Oct 31, 2016), are presented here. This ongoing study is registered with Clinicaltrials.gov, number NCT01715285.Between Feb 12, 2013, and Dec 11, 2014, 1199 patients were
follow-up and focus on tumor volume. Patients and Methods In this phase III study, 790 patients with metastatic hormone-sensitive prostatecancer were equally randomly assigned to receive either ADT in combination with docetaxel 75 mg/m2 for up to six cycles or ADT alone. The primary end point of the study was overall survival (OS). Additional analyses of the prospectively defined low- and high-volume disease subgroups were performed. High-volume disease was defined as presence of visceral metastases (...) Chemohormonal Therapy in Metastatic Hormone-Sensitive ProstateCancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostatecancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in ProstateCancer) trial with more mature
Salvage Pelvic Lymph Node Dissection After Fluciclovine Positron Emission Tomography/Computed Tomography Detected ProstateCancer Recurrence Background: Multiple new systemic agents have been targeted to metastatic prostatecancer, with decreased progression of disease but no cure. Surgical management of metastatic disease has been gaining interest, primarily in the setting of high-risk prostatectomies. However, metastasis-directed surgical intervention has been employed in rare scenarios (...) , especially in oligometastatic disease. We report here on a salvage robot-assisted pelvic lymph node dissection for a solitary metastatic site. Case Presentation: A 63-year-old Hispanic man who was initially treated with prostatectomy for intermediate risk cancer developed rapid biochemical recurrence. After salvage radiation, fluciclovine positron emission tomography (PET)/computed tomography (CT) scan showed a solitary pelvic lymph node metastasis. A robot-assisted laparoscopic pelvic lymph node
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited.In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostatecancer who had (...) not undergone biopsy previously to undergo MRI, with or without targeted biopsy, or standard transrectal ultrasonography-guided biopsy. Men in the MRI-targeted biopsy group underwent a targeted biopsy (without standard biopsy cores) if the MRI was suggestive of prostatecancer; men whose MRI results were not suggestive of prostatecancer were not offered biopsy. Standard biopsy was a 10-to-12-core, transrectal ultrasonography-guided biopsy. The primary outcome was the proportion of men who received
with prostatecancer was higher in the intervention group (n = 8054; 4.3%) than in the control group (n = 7853; 3.6%) (RR, 1.19 [95% CI, 1.14 to 1.25]; P < .001). More prostatecancertumors with a Gleason grade of 6 or lower were identified in the intervention group (n = 3263/189 386 [1.7%]) than in the control group (n = 2440/219 439 [1.1%]) (difference per 1000 men, 6.11 [95% CI, 5.38 to 6.84]; P < .001). In the analysis of all-cause mortality, there were 25 459 deaths in the intervention group vs 28 306 (...) Effect of a Low-Intensity PSA-Based Screening Intervention on ProstateCancer Mortality: The CAP Randomized Clinical Trial. Prostatecancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment.To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostatecancer-specific mortality.The Cluster Randomized Trial of PSA Testing
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 ProstateCancer. The optimal treatment for Gleason score 9-10 prostatecancer is unknown.To compare clinical outcomes of patients with Gleason score 9-10 prostatecancer after definitive treatment.Retrospective cohort study in 12 tertiary centers (11 in the United States, 1 in Norway), with 1809 patients treated (...) between 2000 and 2013.Radical prostatectomy (RP), external beam radiotherapy (EBRT) with androgen deprivation therapy, or EBRT plus brachytherapy boost (EBRT+BT) with androgen deprivation therapy.The primary outcome was prostatecancer-specific mortality; distant metastasis-free survival and overall survival were secondary outcomes.Of 1809 men, 639 underwent RP, 734 EBRT, and 436 EBRT+BT. Median ages were 61, 67.7, and 67.5 years; median follow-up was 4.2, 5.1, and 6.3 years, respectively. By 10 years
Prostatecancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Prostatecancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone | European Medicines Agency Search Search Menu Prostatecancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Press release 09/03/2018 Ongoing clinical study shows an increased risk of death and fractures with the combination The European Medicines Agency (EMA) has recommended contraindicating (...) the use of the prostatecancer medicine Xofigo (radium-223 dichloride) with Zytiga (abiraterone acetate) and prednisone/prednisolone, due to an increased risk of death and fractures with this combination. EMA's ( ) has reviewed the preliminary data from an ongoing clinical study in metastatic prostatecancer patients. In this study 34.7% of patients treated with Xofigo, Zytiga and prednisone/prednisolone have died so far, compared with 28.2% of patients given placebo, Zytiga and prednisone
Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostatecancer Randomized evidence for extreme hypofractionation in prostatecancer is lacking. We aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and extreme hypofractionated radiation in a phase 3 randomized trial.We analyzed the results of the first 75 patients in our (...) phase 3 trial, comparing 38 Gy relative biologic effectiveness (RBE) in 5 fractions (n = 46) versus 79.2 Gy RBE in 44 fractions (n = 29). Patients received proton radiation using fiducials and daily image guidance. We evaluated American Urological Association Symptom Index (AUASI), adverse events (AEs), and Expanded Prostate Index Composite (EPIC) domains. The primary endpoint of this interim analysis was the cumulative incidence of grade 2 (G2) or higher AEs. The randomized patient allocation
Apalutamide Treatment and Metastasis-free Survival in ProstateCancer. Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostatecancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostatecancer who were at high risk for the development of metastasis.We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostatecancer (...) of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group. The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%).Among men with nonmetastatic castration-resistant prostatecancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN
Risk of prostatecancer across different racial/ethnic groups in men with diabetes: a retrospective cohort study To examine the associations between prostatecancer, diabetes and race/ethnicity.Using administrative data from British Columbia, Canada for the period 1994 to 2012, we identified men aged ≥50 years with and without diabetes. Validated surname algorithms identified men as Chinese, Indian or of other race/ethnicity. Multivariable Cox regression was used to estimate adjusted risks (...) of prostatecancer according to diabetes status and race/ethnicity.Our cohort of 160 566 men had a mean (sd) age of 64.7 (9.4) years and a median of 9 years' follow-up. The incidence rates of prostatecancer among those with and without diabetes were 177.4 (171.7-183.4) and 216.0 (209.7-222.5) per 1000 person-years, respectively. The incidence among Chinese men was 120.9 (109.2-133.1), among Indian men it was 144.1 (122.8-169.0) and in men of other ethnicity it was 204.8 (200.2-209.5). Diabetes
Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized ProstateCancer Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostatecancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized (...) prostatecancer. Materials and Methods Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups. Results With a median follow-up of 8 years for patients in the training cohort